459-00-7

Basic information

• Product Name: 2-Methyl-1-(4-(trifluoroMethyl)phenyl)propan-2-aMine
• Synonyms: 2-Methyl-1-(4-(trifluoroMethyl)phenyl)propan-2-aMine
• CAS NO: 459-00-7
• Molecular Formula: C₁₁H₁₄F₃N
• Molecular Weight: 217.2307696
• Mol File: 459-00-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Methyl-1-(4-(trifluoroMethyl)phenyl)propan-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-1-(4-(trifluoroMethyl)phenyl)propan-2-aMine(459-00-7)
• EPA Substance Registry System: 2-Methyl-1-(4-(trifluoroMethyl)phenyl)propan-2-aMine(459-00-7)

Safety Data

• Hazardous Substances Data: 459-00-7(Hazardous Substances Data)

Usage

General Description

2-Methyl-1-(4-(trifluoroMethyl)phenyl)propan-2-aMine, also known as 4-MTA, is a chemical compound with a molecular formula C11H14F3N. It is a psychoactive drug that belongs to the amphetamine class and is structurally related to MDMA. 4-MTA acts as a stimulant and entactogen, inducing feelings of empathy, emotional openness, and increased sociability. It affects the levels of neurotransmitters such as serotonin, dopamine, and norepinephrine in the brain, leading to its psychoactive effects. The use of 4-MTA has been associated with adverse health effects, including hyperthermia, seizures, and even fatalities. It is classified as a controlled substance in many countries due to its potential for abuse and harm.

Upstream product

• 182217-79-4 N-[1,1-dimethyl-2-(4-trifluoromethyl-phenyl)-ethyl]-formamide 
• 864878-71-7 2-methyl-1-(4-(trifluoromethyl)phenyl)propan-2-ol 
• 1379575-71-9 1-(2-azido-2-methylpropyl)-4-(trifluoromethyl)benzene 

Downstream Products

• 1379575-70-8 tert-butyl 2-(2-methyl-1-(4-(trifluoromethyl)phenyl)propan-2-yl)hydrazinecarboxylate 

Relevant articles and documents

Method for producing hematopoietic stem cells using pyrazole compounds

An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R1 to R8 are as defined in the description).

Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as β2-adrenoceptor agonists

Novel β2-agonists with a 5-hydroxy-4H-benzo[1,4]oxazin-3-one moiety as head group are described. Systematic chemical variations at the phenethylamine residue of these compounds lead to the discovery of compound 6m as potent, full agonist of the β2-adrenoceptor with a high β1/β2-selectivity. Molecular modeling revealed an interaction between the carboxylic acid group of 6m and a lysine residue (K305) of the β2-receptor as putative explanation for the high observed selectivity. Further, compound 6m displayed in a guinea pig in vivo model a complete reversal of acetylcholine induced bronchoconstriction which lasted over the complete study time of 5 h.